TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$3.18B
• Dividend Yield: N/A
• Average Volume (3M): 240.51K
• Price to Earnings (P/E): 392.4
• Beta (1Y): 0.53
• Revenue Growth: 9.41%
• EPS Growth: -32.69%
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 141,880
• 30 Day Avg. Volume: 240,506
• PEG Ratio: -0.18
• Price to Book (P/B): 1.67
• Price to Sales (P/S): 1.11
• P/FCF Ratio: -170.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: HK$4.50 ▲(80.00% Upside)

The score is driven primarily by improved financial performance (stronger profitability and a solid balance sheet), while the biggest offsets are extremely overbought technical conditions (RSI 96.9) and very expensive valuation (P/E ~399).

Positive Factors

Balance sheet strength

A relatively low debt-to-equity ratio and stable equity base provide durable financial flexibility for R&D and commercialization cycles. Strong balance sheet reduces refinancing and solvency risk, enabling continued investment in drug development and strategic partnerships over the next several quarters.

Profitability turnaround

Margins moving from negative to positive and improved EBIT/EBITDA indicate structural operating improvements across cost control and pricing. Sustained positive margins support reinvestment capacity and make future product launches or scaling more financially viable over the coming 2–6 months.

Focused biologics and oncology franchise

A focused franchise in oncology and immunology with biologics and monoclonal antibodies aligns with high, durable clinical need and pricing power. This specialization supports sustainable revenue opportunity, higher barriers to entry, and long-term partnerships with hospitals and pharma collaborators.

Negative Factors

Persistent negative free cash flow

Continued negative free cash flow signals that operating cash generation does not yet cover capital and growth spending, raising liquidity and financing risk. Over several months this can force external financing or cutbacks in R&D/commercialization, constraining strategic options.

Earnings volatility / EPS decline

A material decline in EPS highlights earnings volatility and potential pressure on profitability drivers. Persistent EPS contraction undermines internal funding for pipeline and commercialization, increasing reliance on external capital and exposing the company to execution risk over the medium term.

Historical revenue volatility

Prior periods of negative revenue growth suggest the business can experience operational or market setbacks. This history indicates execution and demand risk that could re-emerge, making forward revenue consistency and planning for launch milestones less certain over the next few quarters.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.

How the Company Makes Money

TOT BIOPHARM generates revenue primarily through the sale of its biopharmaceutical products, which include proprietary drugs and therapies developed in-house. The company has a diverse revenue model that includes direct sales to hospitals and clinics, as well as partnerships with other pharmaceutical companies for co-development and distribution. Additionally, TOT BIOPHARM may earn revenue through licensing agreements, where it licenses its technology or products to other companies for further development or commercialization. Significant partnerships with research institutions and collaborations with global pharmaceutical firms also contribute to the company's earnings, enhancing its market reach and capabilities in product development.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

Income statement strength (75) and a solid balance sheet (80) show a meaningful turnaround with improved margins and prudent leverage, but cash flow is weaker (60) due to continued negative free cash flow, which raises liquidity sustainability risk.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07B	1.10B	780.63M	442.18M	76.33M	22.49M
Gross Profit	758.56M	782.43M	573.99M	370.62M	27.47M	15.53M
EBITDA	43.83M	84.96M	10.45M	-5.41M	-224.51M	-254.71M
Net Income	7.26M	34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet
Total Assets	1.48B	1.51B	1.43B	1.26B	710.26M	641.18M
Cash, Cash Equivalents and Short-Term Investments	383.98M	381.26M	351.60M	517.63M	155.38M	225.53M
Total Debt	397.20M	395.47M	345.65M	289.53M	208.56M	7.41M
Total Liabilities	744.74M	779.12M	739.41M	546.59M	375.17M	58.83M
Stockholders Equity	731.68M	729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow
Free Cash Flow	48.42M	-7.17M	-146.77M	-180.19M	-290.45M	-285.30M
Operating Cash Flow	123.43M	116.40M	56.43M	59.93M	-175.14M	-263.12M
Investing Cash Flow	-80.23M	-122.50M	-164.10M	-282.76M	-108.39M	12.53M
Financing Cash Flow	-7.09M	34.18M	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Positive. The current price of 2.5 is below the 20-day moving average (MA) of 3.51, below the 50-day MA of 2.58, and above the 200-day MA of 2.20, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 81.09 is Negative, neither overbought nor oversold. The STOCH value of 20.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	60 Neutral	HK$3.18B	392.38	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6622	47 Neutral	HK$2.02B	-6.68	-14.84%	―	-38.38%	-22.12%
2511	46 Neutral	HK$1.36B	-3.85	-67.27%	―	―	47.42%
2181	45 Neutral	HK$2.23B	-75.00	-25.72%	―	178.36%	86.74%
2185	44 Neutral	HK$1.28B	-13.25	-14.87%	―	―	22.65%
6978	43 Neutral	HK$1.60B	-6.01	―	―	―	27.90%

TOT BIOPHARM International Co. Ltd. Corporate Events

TOT BIOPHARM Receives Voluntary Cash Offer at 99% Premium

Citigroup Global Markets Asia Limited will, on behalf of an offeror, launch voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd. not already owned by the offeror and its concert parties at HK$4.00 per share and to cancel all outstanding share options. The offer price represents a roughly 99% premium to the company’s last undisturbed trading price and will not be increased, signalling a potentially significant change of control that could constitute a major transaction for the offeror and a discloseable transaction for Wuxi Biologics, while trading in the company’s shares is set to resume as the market digests the proposed deal and its implications for minority shareholders and the company’s future ownership structure.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Clarifies Pre-IPO Share Option Scheme and Expiry in Supplemental Annual Report

BioDlink International Company Limited has issued a supplemental announcement to its 2024 annual report, providing additional details on its Pre-IPO Share Option Scheme and related equity incentive plans as required under Hong Kong listing rules. The company disclosed that up to 16,969,000 shares, representing about 2.20% of its issued share capital at the annual report date, may be issued under the Pre-IPO scheme, clarified eligibility (employees and former employees acting as consultants), vesting conditions tied to seniority and R&D milestones, option exercise procedures, and the pricing mechanism, including adjustments for changes in share capital and dividends. It also confirmed that the grant period for the Pre-IPO scheme has expired, meaning no new options can be issued under it, signaling a shift toward its newer restricted share award schemes and offering investors greater transparency on dilution and long-term incentive alignment with the company’s research-focused performance targets.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Requests Trading Halt Pending Inside Information Announcement

BioDlink International Company Limited, a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange (stock code 1875), announced the composition of its board, comprising an executive director, a non-executive director and three independent non-executive directors. The company has requested a halt in trading of its shares on the Hong Kong Stock Exchange from 9:00 a.m. on 29 December 2025, pending the release of an announcement containing inside information, signaling that potentially price-sensitive developments are forthcoming and placing investors temporarily in a holding pattern until further disclosure is made.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Grants 13.35 Million Restricted Shares to Staff Under 2024 Incentive Scheme

BioDlink International Company Limited has granted 13,350,000 restricted share awards, equivalent to about 1.73% of its issued share capital, to eight non-director employees under its 2024 Restricted Share Award Scheme. The awards, priced at HK$0.6 per share compared with a market price of HK$2.03 at the grant date, will vest in four equal tranches subject to performance targets tied to CDMO revenue and group EBITDA for 2026–2027 and multi‑year service conditions, reflecting management’s use of equity incentives to align key staff with the company’s medium‑term growth and profitability objectives, particularly in its CDMO business, although the scheme does not include a broader clawback mechanism beyond forfeiture on dismissal or misconduct.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Reports 23% Revenue Decline Amidst Market Competition

BioDlink International Company Limited, along with its subsidiaries, operates in the biotechnology sector, focusing on the development and commercialization of biopharmaceutical products. The company is listed on the Hong Kong Stock Exchange and has a significant shareholder, Center Laboratories, Inc., listed on the Taipei Exchange. The company announced a 23% decrease in revenue for the nine months ending September 30, 2025, compared to the same period in 2024, due to increased market competition for its self-developed products. This financial update, extracted from unaudited management accounts, highlights fluctuating operational results, advising shareholders and investors to exercise caution.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Announces Leadership Changes Amidst Resignations

BioDlink International Company Limited announced changes in its leadership, with Dr. Liu and Ms. Yeh-Huang resigning from their respective positions due to family reasons. This reshuffling may impact the company’s strategic direction and governance, as it involves key roles such as the executive director, chief executive officer, and members of the Strategy and ESG Committee.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.